Acrivon Therapeutics Inc.... (ACRV)
Acrivon Therapeutics Common Stock Statistics
Share Statistics
Acrivon Therapeutics Common Stock has 31.35M shares outstanding. The number of shares has increased by 1.54% in one year.
Shares Outstanding | 31.35M |
Shares Change (YoY) | 1.54% |
Shares Change (QoQ) | 0.69% |
Owned by Institutions (%) | n/a |
Shares Floating | 21.75M |
Failed to Deliver (FTD) Shares | 6 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.08M, so 3.47% of the outstanding shares have been sold short.
Short Interest | 1.08M |
Short % of Shares Out | 3.47% |
Short % of Float | 4.91% |
Short Ratio (days to cover) | 15.38 |
Valuation Ratios
The PE ratio is -25.25 and the forward PE ratio is -1.88. Acrivon Therapeutics Common Stock's PEG ratio is 0.28.
PE Ratio | -25.25 |
Forward PE | -1.88 |
PS Ratio | 0 |
Forward PS | 0.5 |
PB Ratio | 11.51 |
P/FCF Ratio | -29.72 |
PEG Ratio | 0.28 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acrivon Therapeutics Common Stock.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.55, with a Debt / Equity ratio of 0.02.
Current Ratio | 10.55 |
Quick Ratio | 10.55 |
Debt / Equity | 0.02 |
Debt / EBITDA | -0.04 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.07M |
Employee Count | 75 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -73.87% in the last 52 weeks. The beta is 0.86, so Acrivon Therapeutics Common Stock's price volatility has been higher than the market average.
Beta | 0.86 |
52-Week Price Change | -73.87% |
50-Day Moving Average | 5.12 |
200-Day Moving Average | 6.8 |
Relative Strength Index (RSI) | 20.98 |
Average Volume (20 Days) | 106.38K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -89.2M |
Net Income | -80.56M |
EBITDA | -89.2M |
EBIT | n/a |
Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 39.82M in cash and 3.65M in debt, giving a net cash position of 36.17M.
Cash & Cash Equivalents | 39.82M |
Total Debt | 3.65M |
Net Cash | 36.17M |
Retained Earnings | -196.98M |
Total Assets | 196.59M |
Working Capital | 164.41M |
Cash Flow
In the last 12 months, operating cash flow was -65.67M and capital expenditures -2.77M, giving a free cash flow of -68.44M.
Operating Cash Flow | -65.67M |
Capital Expenditures | -2.77M |
Free Cash Flow | -68.44M |
FCF Per Share | -0.2 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ACRV does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for ACRV is $18, which is 934.5% higher than the current price. The consensus rating is "Buy".
Price Target | $18 |
Price Target Difference | 934.5% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Scores
Altman Z-Score | -0.3 |
Piotroski F-Score | 3 |